Posted in | News | Gold

Riverstone Resources Intercepts Gold Mineralization at Goulagou I Zone

Riverstone Resources has announced additional drilling results from the Goulagou I zone of the Karma Project in Burkina Faso, West Africa.

The company drills ten holes as part of the current reverse circulation (RC) drilling campaign at the Goulagou I zone. It has planned the drill program for fill-in and extension of the existing mineralization at Goulagou I. This mineralization stays open in all the directions, mainly to the western direction and at the depth. The assay results from more than 40 holes drilled recently at this Goulagou I zone are being expected.

The company has encountered 1.09 g/t gold over 26.0 m in the hole 206, 1.32 g/t gold over 6 m and 0.83 g/t gold over 40.0 m in the hole 210 and 1.44 g/t gold over 32 m, 0.98 g/t gold over 64.0 m in the hole 211. It has obtained drilling results from holes 205 to 214. The holes 208 and 209 have not produced material values.

The company includes this Goulagou I zone as part of the Karma deposit hosting a NI 43-101 compliant resource. The report includes indicated category of 810,000 oz gold in 22,845,000 t grading 1.10 g/t gold and inferred category of 1,119,100 oz gold in 44,100,000 t grading 0.79 g/t gold. This Goulagou property is under an Option to Purchase agreement between Riverstone and Golden Star Resources.

All the RC samples were tested by Abilab Burkina SARL laboratories using standard fire assay and atomic absorption methods.


Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Riverstone Resources Inc.. (2019, February 18). Riverstone Resources Intercepts Gold Mineralization at Goulagou I Zone. AZoMining. Retrieved on March 04, 2024 from

  • MLA

    Riverstone Resources Inc.. "Riverstone Resources Intercepts Gold Mineralization at Goulagou I Zone". AZoMining. 04 March 2024. <>.

  • Chicago

    Riverstone Resources Inc.. "Riverstone Resources Intercepts Gold Mineralization at Goulagou I Zone". AZoMining. (accessed March 04, 2024).

  • Harvard

    Riverstone Resources Inc.. 2019. Riverstone Resources Intercepts Gold Mineralization at Goulagou I Zone. AZoMining, viewed 04 March 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Azthena logo powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.